Gruppo Oncologico Del Nord-ovest

This study tests whether a postbiotic supplement (Postbiotix-HLA™) can reduce immune-related side effects in 45 people with recurrent or metastatic head and neck cancer who are receiving the immunotherapy drug pembrolizumab. Participants will take either the supplement or a place…

This study tests whether giving a short course of targeted drugs before surgery can improve outcomes for people with colorectal cancer that can be removed. About 197 participants will receive a treatment matched to their tumor's genetic makeup, followed by standard surgery. The g…

This study tests a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with HER-2 positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see how well the drugs shrink tumors. About …

This Phase 3 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (FOLFOXIRI) and bevacizumab helps people with a specific type of metastatic colorectal cancer live longer without their disease getting worse. The study enrolls 238 adults whose t…